Skip to main content

Table 1 Performances of biomarkers for the diagnosis of HCC patients

From: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma

  AUC(95%CI) Cutoff value Sensitivity(%)(95%CI) Specificity(%)(95%CI) Z test P Value
HCC vs Healthy controls
PIVKA-II 0.90 (0.88–0.94) 35.60mAU/ml 83.93 (77.63–88.71) 91.50 (86.01–94.97)   
AFP 0.77 (0.72–0.82) 17.76 ng/ml 64.29 (56.80–71.14) 90.20 (84.45–93.97)   
PIVKA-II + AFP 0.94 (0.92–0.97)*   87.50 (81.65–91.68) 92.50 (86.01–94.97) 6.756 < 0.01
HCC vs Benign liver diseases
PIVKA-II 0.85 (0.81–0.89) 43.47mAU/ml 81.55 (75.00–86.68) 86.00 (79.54–90.66)   
AFP 0.72 (0.66–0.77) 21.47 ng/ml 63.10 (55.58–70.02) 84.67 (78.04–89.56)   
PIVKA-II + AFP 0.90 (0.87–0.94)*   81.95 (74.35–86.17) 89.33 (83.38–93.33) 6.744 < 0.01
  1. *P < 0.01 in comparison with AFP